Merck Serono announces Global Grants Programme

Published: 9-Jul-2014
Research & Development Finance Pharmaceutical

Pledges €20m to advance innovation and medical education


Merck Serono, the biopharmaceutical division of Merck, has announced the Merck Global Grants programme that underscores its commitment to funding scientific innovation and independent medical education around the world. The initiative encompasses Merck's complete grants portfolio, including the Grants for Innovation in Research and Grants for Independent Medical Education.

The programme has a total annual investment of €20m across all grants programmes, highlighting the company’s efforts to promote advances in the field of medicine, addressing gaps in healthcare knowledge, and improving the quality of patient care.

'Merck Serono has a long-standing reputation as a strong advocate for scientific innovation and medical education, believing that both are integral to helping healthcare professionals bring enhanced care to patients,' said Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at Merck Serono.

The Grants for Innovation in Research identify and fund promising research across the biopharmaceutical industry, including academia, research centres, start-ups and independent researchers. Specific grants focus on areas in which Merck Serono has a strong R&D and commercial presence, including oncology, multiple sclerosis, fertility and growth innovation.

The programme includes the launch of an online portal which allows transparent and ethical interactions with medical education providers. Funding is provided to educational institutions such as universities, medical education providers, medical scientists and scientific organisations.

  • Companies:
  • Merck Electronics KGaA
See more

You may also like

Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Read more
Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers

Trending Articles

  1. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
  2. Dual-chamber packaging systems as a simplification factor in the supply chain Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
  3. BioPharmaSpec expands its biopharma discovery and preclinical capabilities with three new facilities The contract research organisation (CRO) has expanded its European presence with three facilities, which are catered for biopharmaceutical drug discovery and preclinical characterisation
  4. Efficient PFAS-free degassing of aqueous solutions New silicone-based degassing chamber eliminates the risk of PFAS contamination
  5. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers
Manufacturing

Merck opens $63m CDMO facility to handle HPAPIs

The industry expert has announced that its Life Science business sector has doubled its highly potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of this facility
Regulatory

Merck announces collaboration with Agilent to fill PAT gap for downstream processing

Collaboration will help to enable real-time release and Bioprocessing 4.0
Research & Development

BioMed X Institute and Merck begin second immunology project

Team TDA will join the three ongoing research groups sponsored by Merck, which follow four completed projects
Research & Development

eTheRNA announces mRNA research agreement with Merck

The ongoing pandemic has underlined the capability for mRNA vaccines as a therapeutic modality
Research & Development

BioMed X completes fourth oncology project with Merck

The next project team: “Synthetic Lethality in DNA Repair” (SDR) is led by Dr Özdemirhan Serçin, who was a postdoctoral researcher in the DDC teamv
Manufacturing

Merck expands technology and capacity for ADC manufacturing

“ADCs have experienced remarkable growth, with commercially approved ADCs tripling in the past three years”
Subscribe now